Sanofi Taking $118.5M Charge, Seeks Restrictive Label for Dengue Vaccine

Sanofi said it expects to take a fourth-quarter charge “in the range of €100 million” ($118.5 million) to reflect lowered projected sales for its pioneering dengue vaccine Dengvaxia ® after long-term clinical trial data showed the vaccine could increase the severity of the disease in people who were not previously infected.Sanofi cited an analysis of six years of clinical data for its revised finding that Dengvaxia—the world’s first approved vaccine for dengue&md